Policy

Need for Biosimilar Cooperation Among Hospitals, Infusion Centers, and Payers Is Identified

October 22nd 2020

By Skylar Jeremias

Overcoming biosimilar uptake barriers will take collaboration and policy change by hospitals, infusion clinics, and health plans, presenters said at the Academy of Managed Care Pharmacy Nexus 2020 Virtual conference.

Avalere: Step Therapy May Exacerbate Patient, Payer Costs

October 19th 2020

By Tony Hagen

Article

An Avalere analysis suggests costs are more moderate and lower under a no–step therapy scenario for patients with Crohn disease.

Case Study: Dean Foods Attempts Savings via Specialty Carve-out

October 17th 2020

By Skylar Jeremias

Article

Before its acquisition this year, Dean Foods attempted a specialty drug carve-out to save with biosimilars and generics.

International Presenters Share Tips on Beefing Up Biosimilar Use

October 9th 2020

By Skylar Jeremias

Article

As the United States continues to struggle to increase biosimilar uptake, presenters at the DIA 2020 Biosimilars Conference offered insight into what other countries have done to encourage biosimilar use.

Report: Biosimilar Savings Have Grown, but Uptake Barriers Remain

September 30th 2020

By Skylar Jeremias

Article

Over the past decade, savings from biosimilars have grown; however, there remain barriers that prevent biosimilar savings from reaching their full potential, according to a report from the Association for Accessible Medicines.

Report: Germany Has Not Fully Realized Its Biosimilar Potential

September 29th 2020

By Deana Ferreri, PhD

Article

Germany could eke out more gains from biosimilars on top of its already impressive savings, investigators write.

Stakeholders Joust Over Biosimilar Availability at PCOC20

September 25th 2020

By Tony Hagen

Article

A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.

Patt: Payers Could Save More With Biosimilars

September 25th 2020

By Tony Hagen

Article

Debra Patt, MD, PhD, MBA, discusses issues affecting biosimilar uptake at the Patient-Centered Oncology Care® 2020 virtual conference.

Report: Prescription Drug Costs Can Be Lowered Without Legislation

September 23rd 2020

By Skylar Jeremias

Article

Much emphasis is placed on the value of congressional action to reduce prescription costs, but the Center for American Progress suggests there is an existing toolkit to accomplish this objective.

Report: Lack of Biosimilar Competition Contributed to Billions in Lost Savings

September 21st 2020

By Skylar Jeremias

Article

The United States has missed out on almost $20 billion in savings as a result of not having a competitive biosimilar market, according to findings from the Pacific Research Institute.